Insider filing · RLMD
Maged Shenouda
Chief Financial Officer
profile →
Relmada Therapeutics, Inc.
RLMD · Healthcare · 8 filings in 24 months
ticker →
Maged Shenouda bought $844K of Relmada Therapeutics (RLMD)
Executed Sep 9, disclosed Sep 11, 2 days later.
Value, as filed
$844K
200,000 sh across 2 lots
Executed
Sep 9
the trade date, as filed
Disclosed
Sep 11
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
not yet measured
Not yet measured: the 21-session window has not closed, or the prices around it are not on record.
The filer
MSMaged Shenouda (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +48.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of RLMD (500,000 sh × $2.20, as filed), executed Nov 5 2025.
The name
RLMDHealthcare · Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Maged Shenouda in RLMD
RLMDPURCHASE
Relmada Therapeutics, Inc.
$1.1M500,000 sh × $2.20
Exec Nov 5 2025
Filed Nov 6 2025 · 7:30 AM ET